Lilly plans new $2.5B manufacturing plant as obesity drug demand ramps up
Jonathan GardnerSenior Reporterย Biopharma Dive Following the approval of Zepbound, Lilly is adding capacity to avert shortages and restricted access. Dive Brief: Eli Lilly is spending $2.5 billion toย build a new manufacturing plantย to expand capacity for injectable drugs and devices, including its weight-loss treatment Zepbound and diabetes shot Mounjaro, as demand for metabolic medicines from […]
Lilly plans new $2.5B manufacturing plant as obesity drug demand ramps up Read More ยป